Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) SVP Brian David Archbold sold 1,151 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $101.27, for a total value of $116,561.77. Following the completion of the transaction, the senior vice president owned 3,710 shares of the company’s stock, valued at $375,711.70. The trade was a 23.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mesa Laboratories Stock Performance
Shares of NASDAQ MLAB traded down $4.85 during trading hours on Wednesday, reaching $94.84. The stock had a trading volume of 154,655 shares, compared to its average volume of 136,917. The business’s fifty day moving average is $101.88 and its two-hundred day moving average is $90.54. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. The company has a market cap of $523.96 million, a price-to-earnings ratio of 79.03 and a beta of 0.94. Mesa Laboratories, Inc. has a twelve month low of $55.45 and a twelve month high of $113.99.
Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last issued its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The firm had revenue of $63.72 million during the quarter, compared to analyst estimates of $65.21 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. During the same quarter in the previous year, the company posted ($1.31) earnings per share.
Mesa Laboratories Announces Dividend
Institutional Trading of Mesa Laboratories
Large investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. grew its position in Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 322 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Mesa Laboratories in the fourth quarter valued at $27,000. Kestra Advisory Services LLC bought a new stake in Mesa Laboratories in the fourth quarter valued at $55,000. BNP Paribas Financial Markets grew its position in Mesa Laboratories by 30.9% in the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 243 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Mesa Laboratories by 432.9% in the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after acquiring an additional 684 shares during the period. 90.60% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings lowered Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Mesa Laboratories has an average rating of “Reduce” and an average target price of $94.00.
Read Our Latest Analysis on Mesa Laboratories
About Mesa Laboratories
Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.
The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.
Further Reading
- Five stocks we like better than Mesa Laboratories
- Insiders Are Selling These 3 Stocks—Should Investors Be Concerned?
- After SpaceX, Amazon Could Be The Next Best Space Stock
- 3 Stocks to Watch If the Strait of Hormuz Reopens
- Draining the Tank: Big Oil Runs on Fumes
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
